Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own0.90% Shs Outstand162.75M Perf Week-8.11%
Market Cap9.11B Forward P/E- EPS next Y-0.67 Insider Trans-12.91% Shs Float159.50M Perf Month2.96%
Income-162.10M PEG- EPS next Q-0.43 Inst Own98.40% Short Float6.81% Perf Quarter-27.94%
Sales609.80M P/S14.95 EPS this Y11.90% Inst Trans-1.32% Short Ratio9.31 Perf Half Y-14.87%
Book/sh8.57 P/B6.53 EPS next Y- ROA-11.80% Target Price80.36 Perf Year6.57%
Cash/sh2.85 P/C19.68 EPS next 5Y23.00% ROE-13.80% 52W Range47.75 - 84.37 Perf YTD4.67%
Dividend- P/FCF- EPS past 5Y-14.00% ROI-24.00% 52W High-33.63% Beta2.16
Dividend %- Quick Ratio3.30 Sales past 5Y18.00% Gross Margin88.80% 52W Low17.28% ATR2.71
Employees1100 Current Ratio3.70 Sales Q/Q25.20% Oper. Margin-35.20% RSI (14)36.06 Volatility4.46% 4.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-225.30% Profit Margin-26.60% Rel Volume1.04 Prev Close58.63
ShortableYes LT Debt/Eq0.00 EarningsJan 24 AMC Payout- Avg Volume1.17M Price56.00
Recom2.20 SMA20-6.65% SMA50-10.56% SMA200-12.59% Volume1,214,616 Change-4.49%
Oct-26-18Reiterated Barclays Overweight $95 → $90
Oct-26-18Downgrade BofA/Merrill Neutral → Underperform
Sep-25-18Initiated Leerink Partners Outperform
Sep-07-18Resumed Piper Jaffray Neutral
Jul-30-18Reiterated Needham Buy $74 → $79
Jul-27-18Reiterated H.C. Wainwright Buy $77 → $98
Jun-11-18Upgrade SunTrust Hold → Buy
Mar-20-18Resumed Barclays Overweight $74
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Feb-07-18Reiterated Needham Buy $72 → $74
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Oct-24-17Resumed Guggenheim Buy $72
Oct-20-17Upgrade Barclays Equal Weight → Overweight $60 → $70
Oct-06-17Resumed Goldman Neutral
Sep-15-17Initiated RBC Capital Mkts Outperform $58
Mar-16-17Initiated Oppenheimer Perform
Feb-10-17Downgrade BofA/Merrill Neutral → Underperform
Dec-12-16Downgrade Credit Suisse Outperform → Neutral
Dec-06-16Reiterated RBC Capital Mkts Outperform $62 → $72
Dec-10-18 07:45AM  Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose Future Expectations, Projections Moving into 2019 GlobeNewswire
Dec-03-18 09:15PM  Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Business Wire
Dec-02-18 12:00PM  Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting Business Wire
Dec-01-18 12:00PM  Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting Business Wire
Nov-30-18 02:08PM  Seattle Genetics opening Bay Area office to attract talent it can't lure to Bothell American City Business Journals
Nov-26-18 08:00AM  Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting Business Wire
Nov-20-18 11:23AM  What You Must Know About Seattle Genetics Incs (NASDAQ:SGEN) Financial Health Simply Wall St.
Nov-19-18 08:41AM  Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session Zacks
06:55AM  Today's Research Reports on Trending Tickers: Amarin and Seattle Genetics ACCESSWIRE
Nov-16-18 01:53PM  Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment MarketWatch +5.59%
10:52AM  Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas Business Wire
07:59AM  Seattle Genetics' Adcetris Gets Breakthrough Therapy Status Zacks
Nov-15-18 08:00AM  FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas Business Wire
Nov-14-18 08:00AM  Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Nov-08-18 07:05AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Seattle Genetics ACCESSWIRE
Nov-06-18 08:00AM  Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference Business Wire
Nov-05-18 08:00AM  Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Business Wire
Nov-02-18 10:16PM  Edited Transcript of SGEN earnings conference call or presentation 25-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
05:51PM  Microsoft and Seattle Genetics buildings are part of a big Bothell sale American City Business Journals
Nov-01-18 04:05PM  Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program Business Wire
Oct-31-18 07:50AM  New Research: Key Drivers of Growth for Covanta Holding, Seattle Genetics, DSW, Canada Goose, Oaktree Capital Group, and Arthur J. Gallagher Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-30-18 02:50PM  Seattle Genetics: "Now the Hard Work Begins" Motley Fool
Oct-26-18 12:39PM  Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark Zacks -15.38%
12:29PM  Here's Why Seattle Genetics Plummeted Today Motley Fool
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
01:11AM  Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 04:58PM  Seattle Genetics: 3Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports Third Quarter 2018 Financial Results Business Wire
Oct-23-18 06:22AM  Seattle Genetics Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-08-18 06:50PM  Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress Business Wire
Oct-03-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018 Business Wire
07:50AM  Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-01-18 06:45AM  Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma Business Wire +5.24%
Sep-21-18 10:48AM  Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma Business Wire
Sep-19-18 03:18PM  Why Seattle Genetics Inc (NASDAQ:SGEN) Is A Financially Healthy Company Simply Wall St.
Sep-17-18 05:26PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Sep-04-18 08:00AM  Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-14-18 10:55AM  Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit Zacks
01:44AM  (UMRX) Q2 2018 Earnings Conference Call Transcript Motley Fool
Aug-13-18 03:40PM  Edited Transcript of SGEN earnings conference call or presentation 26-Jul-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-10-18 09:35AM  Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2 Zacks
Aug-09-18 10:04AM  Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates Zacks
09:52AM  Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y Zacks
09:35AM  Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales Zacks
09:17AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise Zacks
Aug-08-18 10:49AM  Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2 Zacks
10:21AM  AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss Zacks
10:14AM  VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y Zacks
Aug-07-18 10:52AM  Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected Zacks
Aug-02-18 12:00PM  Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y Zacks
10:35AM  Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track Zacks
Aug-01-18 04:48PM  Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down Zacks
Jul-31-18 02:30PM  Seattle Genetics' Latest Approval Is the Best Yet Motley Fool
Jul-27-18 11:20AM  Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks
08:44AM  Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter Benzinga
Jul-26-18 04:02PM  Seattle Genetics Reports Second Quarter 2018 Financial Results Business Wire
08:20AM  Earnings Preview For Seattle Genetics Benzinga
Jul-23-18 06:00AM  3 Hot Biotech Stocks With More Gains Ahead Investopedia
Jul-20-18 08:10AM  Today's Research Reports on Trending Tickers: PTC Therapeutics and Seattle Genetics ACCESSWIRE
Jul-16-18 07:40AM  Blog Exposure - Seattle Genetics Announces First Patient Dosage in Phase-2 innovaTV 207 Trial for Multiple Solid Tumors ACCESSWIRE
Jul-13-18 08:34AM  Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering Benzinga
Jul-12-18 08:00AM  Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors Business Wire
07:20AM  Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-11-18 06:51PM  Cramer's lightning round: Amazon doesn't always destroyjust look at Roku CNBC
10:41AM  CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer Business Wire
Jul-09-18 08:00AM  Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program Business Wire
Jun-28-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018 Business Wire
Jun-26-18 07:45AM  Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-13-18 08:00AM  Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer Business Wire
Jun-07-18 07:35AM  Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:00AM  Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-04-18 09:00AM  Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting Business Wire
Jun-03-18 09:00AM  Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy Business Wire
09:00AM  Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy PR Newswire
Jun-01-18 12:16PM  3 Biotech Stocks Poised for 12% Gains Investopedia
08:30AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Seattle Genetics ACCESSWIRE
May-28-18 03:23AM  Why Is Seattle Genetics (SGEN) Up 13.3% Since Its Last Earnings Report? Zacks
May-17-18 09:00AM  Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer Business Wire
08:00AM  Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting Business Wire
May-14-18 06:00AM  4 Biotech Stocks Set to Rise By 14% or More Investopedia
May-09-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags Entertainment Corporation New, Leucadia National, Seattle Genetics, and RPC New Research Emphasizes Economic Growth GlobeNewswire
May-04-18 07:30AM  Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA ACCESSWIRE
May-03-18 09:05AM  The Bothell economy: City looks to Lake Union area as model to build up biotech hub American City Business Journals
May-02-18 04:10PM  Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much Motley Fool
08:00AM  Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018 Business Wire
Apr-27-18 11:50PM  Edited Transcript of SGEN earnings conference call or presentation 26-Apr-18 8:30pm GMT Thomson Reuters StreetEvents +5.57%
12:15PM  Why Seattle Genetics Jumped Higher Today Motley Fool
11:06AM  Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top Zacks
05:00AM  Seattle Genetics searches for 10th building in effort to keep up with growth American City Business Journals
Apr-26-18 05:39PM  Seattle Genetics: 1Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports First Quarter 2018 Financial Results Business Wire
Apr-19-18 05:28PM  Seattle Genetics searches for its 10th building to keep up with growth American City Business Journals
Apr-12-18 08:00AM  Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting Business Wire
Apr-05-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018 Business Wire
Mar-28-18 05:02PM  Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion Zacks
Mar-26-18 05:53PM  Seattle Genetics wins FDA approval for cancer drug that could push U.S. sales past $1 billion American City Business Journals +5.14%
08:00AM  Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Mar-23-18 10:28AM  Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus Zacks
Mar-21-18 10:55AM  Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion Zacks
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEODec 10Option Exercise12.1620,148245,000745,761Dec 12 07:31 PM
SIEGALL CLAY BPresident and CEODec 10Sale59.7420,1481,203,545732,613Dec 12 07:31 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.005,00060,000177,329Dec 04 07:37 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale62.145,000310,718172,329Dec 04 07:37 PM
Cline Darren SEVP, CommercialNov 29Sale62.887,000440,16072,556Nov 30 06:32 PM
Cline Darren SEVP, CommercialNov 21Sale56.684,167236,20479,556Nov 21 06:42 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.1620,148245,000746,091Nov 09 05:54 PM
SIEGALL CLAY BPresident and CEONov 08Sale61.5420,1481,239,873732,613Nov 09 05:54 PM
AKKARAJU SRINIVASDirectorOct 30Option Exercise8.385,00041,90037,205Nov 01 05:55 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.1620,148245,000746,550Oct 09 08:13 PM
SIEGALL CLAY BPresident and CEOOct 08Sale77.3920,1481,559,231732,613Oct 09 08:13 PM
SIEGALL CLAY BPresident and CEOSep 17Option Exercise12.1620,148245,000742,544Sep 19 06:36 PM
SIEGALL CLAY BPresident and CEOSep 17Sale76.8420,1481,548,196732,613Sep 19 06:36 PM
HIMES VAUGHN BChief Technical OfficerSep 07Option Exercise12.005,00060,000182,329Sep 11 07:26 PM
HIMES VAUGHN BChief Technical OfficerSep 07Sale76.995,000384,962177,329Sep 11 07:26 PM
SIMPSON TODD EChief Financial OfficerAug 27Sale74.235,427402,856173,565Aug 29 07:40 PM
SIEGALL CLAY BPresident and CEOAug 27Sale74.2325,5141,893,950636,632Aug 29 07:39 PM
LIU JEAN IGC/EVP, Leg AffairsAug 27Sale74.234,123306,05856,741Aug 29 07:37 PM
HIMES VAUGHN BChief Technical OfficerAug 27Sale74.235,530410,502159,376Aug 29 07:35 PM
Cline Darren SEVP, CommercialAug 27Sale74.234,784355,12565,079Aug 29 07:32 PM
SIEGALL CLAY BPresident and CEOAug 21Sale74.9525,0001,873,750662,146Aug 23 08:01 PM
SIEGALL CLAY BSee RemarksAug 09Option Exercise11.0918,831208,836703,857Aug 13 04:47 PM
SIEGALL CLAY BSee RemarksAug 09Sale72.7118,8311,369,153687,146Aug 13 04:47 PM
LIPPMAN MARC EDirectorJul 31Sale69.257,400512,450128,350Aug 02 08:00 PM
SIEGALL CLAY BPresident and CEOJul 09Option Exercise11.0918,832208,847702,356Jul 11 08:28 PM
SIEGALL CLAY BPresident and CEOJul 09Sale69.0718,8321,300,770687,146Jul 11 08:28 PM
Cline Darren SEVP, CommercialJun 12Option Exercise29.1410,086293,91079,831Jun 14 06:31 PM
Cline Darren SEVP, CommercialJun 12Sale69.0012,054831,68869,863Jun 14 06:31 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise11.0918,832208,847705,278Jun 12 07:34 PM
SIEGALL CLAY BPresident and CEOJun 08Sale65.1218,8321,226,341687,146Jun 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.005,00060,000169,906Jun 04 07:11 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale58.475,000292,365164,906Jun 04 07:11 PM
Cline Darren SEVP, CommercialMay 09Option Exercise16.209,000145,79080,831May 11 07:59 PM
SIEGALL CLAY BPresident and CEOMay 09Option Exercise11.0918,832208,847694,922May 11 08:01 PM
SIEGALL CLAY BPresident and CEOMay 09Sale54.9718,8321,035,114687,146May 11 08:01 PM
Cline Darren SEVP, CommercialMay 09Sale55.339,000497,98371,831May 11 07:59 PM
BAKER BROS. ADVISORS LPDirectorMay 08Buy54.02126,3996,828,33945,825,986May 08 05:17 PM
BAKER BROS. ADVISORS LPDirectorMay 07Buy53.70129,7156,966,30545,699,587May 08 05:17 PM
BAKER BROS. ADVISORS LPDirectorMay 04Buy52.68204,53710,775,58245,569,872May 08 05:17 PM
Cline Darren SEVP, CommercialMay 03Sale53.814,000215,23871,831May 07 07:08 PM
BAKER BROS. ADVISORS LPDirectorMay 02Buy52.5769,9473,676,83645,365,335May 02 06:05 PM
BAKER BROS. ADVISORS LPDirectorMay 01Option Exercise10.0820,000201,60044,988,471May 02 06:05 PM
BAKER BROS. ADVISORS LPDirectorMay 01Buy51.36306,91715,764,73645,295,388May 02 06:05 PM
BAKER BROS. ADVISORS LPDirectorApr 30Buy51.06623,13631,816,92544,978,471May 02 06:05 PM
SIEGALL CLAY BPresident and CEOApr 09Option Exercise11.0918,832208,847705,978Apr 11 08:38 PM
SIEGALL CLAY BPresident and CEOApr 09Sale50.5218,832951,393687,146Apr 11 08:38 PM
DRACHMAN JONATHAN GCMO & EVP, R & DMar 20Option Exercise14.1531,039439,134201,973Mar 22 07:04 PM
HIMES VAUGHN BSee RemarksMar 15Option Exercise12.005,00060,000169,906Mar 19 07:35 PM
HIMES VAUGHN BSee RemarksMar 15Sale58.125,000290,604164,906Mar 19 07:35 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise11.0918,832208,847701,214Mar 13 08:43 PM
SIEGALL CLAY BPresident and CEOMar 09Sale57.3218,8321,079,436687,146Mar 13 08:43 PM
DRACHMAN JONATHAN GCMO & EVP, R & DMar 05Option Exercise8.9610,45793,695178,134Mar 07 08:25 PM
DRACHMAN JONATHAN GCMO & EVP, R & DMar 05Sale52.8310,457552,452170,934Mar 07 08:25 PM
WELCH DANIEL GDirectorFeb 13Option Exercise9.3916,881158,46366,100Feb 15 09:21 PM
SIEGALL CLAY BPresident and CEOFeb 09Option Exercise11.0918,832208,847697,546Feb 13 08:19 PM
SIEGALL CLAY BPresident and CEOFeb 09Sale49.7518,832936,818687,146Feb 13 08:19 PM
BAKER BROS. ADVISORS LPDirectorFeb 01Buy52.003,846,153199,999,95644,355,335Feb 05 04:00 PM
SIEGALL CLAY BPresident and CEOJan 11Option Exercise11.0918,832208,847697,716Jan 16 08:08 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJan 11Option Exercise11.0619,416214,705170,934Jan 16 08:04 PM
SIEGALL CLAY BPresident and CEOJan 11Sale51.7118,832973,873687,146Jan 16 08:08 PM